Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-102 in pediatric cerebral X-linked adrenoleukodystrophy before HSCT
2019-000654-59Phase 2Active
- Sponsor
- Minoryx Therapeutics
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leriglitazone in X-linked adrenoleukodystrophy (X-ALD) and adrenoleukodystrophy (ALD), sponsored by Minoryx Therapeutics. Primary endpoint: Progression of cerebral lesions on serial MRI. Started Apr 2019; status: active.
02
Drugs
leriglitazone
03
Conditions
X-linked adrenoleukodystrophy (X-ALD)adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on 2019-000654-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000654-59.